NGE Capital Limited

NGE

NGE Capital Ltd is a AU-based company operating in industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2007-12-28. NGE Capital Limited is an Australia-based internally managed listed investment company. The firm primarily focuses on listed Australian Securities Exchange (ASX) and international equities, with the aim of generating risk-adjusted returns over the medium to long term. Its principal activities are to make investments in listed and unlisted securities. The company offers investors exposure to a concentrated portfolio of high conviction investments. The company offers a flexible investment mandate and invests according to a defined set of investment principles, including only invest in a compelling opportunity, otherwise hold cash; invest based on fundamental analysis; target investments that can generate returns with an adequate margin of safety; and aim to hold a concentrated portfolio of high conviction investments.

Neuren Pharmaceuticals Limited

NEU

Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The firm is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The firm has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.

Norfolk Metals Limited

NFL

Norfolk Metals Ltd. provides exploration services. The firm is a gold and uranium focused explorer with assets located in Tasmania and South Australia respectively. The company holds interest in Roger River Project and the Orroroo Uranium Project. The Roger River Project comprises two granted exploration licenses, EL20/2020, and EL17/2021, which together cover 261 kilometers (km2), located 410 kilometers (km) northwest of the capital city of Hobart, Tasmania. The Project is prospective for gold and copper as indicated by the intense silicification, argillisation and diatreme breccias in close proximity to the Roger River Fault along with carbonate-rich host rocks. The Orroroo Uranium Project comprises two granted exploration licenses, EL6552, and EL6814, which together cover 659km2, located approximately 274 km northwest of the capital city of Adelaide, South Australia within the Walloway Basin.